New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
13:38 EDTBIIB, ABBV, SHPG, GILD, NPSP, AMGN, BMY, CShire selects Citi as adviser to prepare for takeover offers, Reuters reports
Shire (SHPG) has hired Citi (C) as an adviser as it prepares for takeover bids, Reuters reports, citing sources. Bankers in the sector believe Shire could be a attractive to Bristol Myers (BMY), Abbvie (ABBV), Gilead (GILD), Biogen (BIIB) or Amgen (AMGN). Reference Link
News For SHPG;C;NPSP;ABBV;BMY;GILD;BIIB;AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
July 16, 2015
11:13 EDTCCiti to host conference call
2Q15 Fixed Income Investor Review conference call to be held on July 21 at 11 am. Webcast Link
11:07 EDTCCiti says environment still 'challenging,' 'unsettled'
Subscribe for More Information
09:35 EDTCActive equity options trading on open
Subscribe for More Information
09:22 EDTBMY, GILDBristol-Myers says EU approves Evotaz for treatment of HIV-1 infection in adults
Subscribe for More Information
09:08 EDTCOn The Fly: Pre-market Movers
Subscribe for More Information
09:01 EDTBMYuniQure has reached compelling entry point, says Roth Capital
Subscribe for More Information
08:58 EDTCCiti says 'tracking well' to 2015 financial targets
Citigroup says "tracking well" to its 2015 financial targets, with modest revenue growth and positive operating leverage in Citicorp; says Citicorp had efficiency ratio of 55%, Citigroup ROA of 103 bps in 1H15. Says Q2 results show continued progress in challenging environment. Says gaining wallet share, improving efficiency of core franchise, winding down non-core assets, maintaining balance sheet discipline, utilizing deferred tax assets. Comments from slides that will be presented on the Q2 earnings conference call.
08:04 EDTCCiti reports Q2 Citicorp revenue $17.8B, up 2% from a year ago
Reports Q2 Global Consumer Banking revenue $8.5B. ICG revenues increased 6% from the prior year period to $8.9B. Citi Holdings revenues of $1.7B in the second quarter 2015 included CVA/DVA of $9M, compared to negative $1M in the prior year period.
08:03 EDTCCiti reports book value per share of $68.27 at end Q2
Subscribe for More Information
08:02 EDTCCiti CEO says Q2 results show 'very balanced performance' across business lines
Subscribe for More Information
08:01 EDTCCiti reports Q2 common equity tier 1 capital ratio 11.4%
Subscribe for More Information
08:00 EDTCCiti reports Q2 EPS ex-CVA/DVA $1.45, consensus $1.34
Reports Q2 revenue $19.5B, consensus $19.11B. CVA/DVA was $312M, or $196M, in the second quarter 2015, compared to negative $33M in the prior year period. Second quarter 2014 results also included the impact of a $3.8B charge, or $3.7 billion after-tax, to settle legacy RMBS and CDO-related claims.5 Excluding CVA/DVA, revenues were $19.2B, down 2% from the prior year period. Excluding CVA/DVA and the impact of the mortgage settlement in the prior year period, earnings were $1.45 per diluted share, up 17% from prior year earnings of $1.24 per diluted share. Including CVA/DVA, EPS was $1.51.
July 15, 2015
16:00 EDTCOptions Update; July 15, 2015
Subscribe for More Information
15:27 EDTCCiti July 56.5 straddle priced for 2.4% movement into Q2
14:53 EDTCNotable companies reporting before tomorrow's open
Subscribe for More Information
14:05 EDTCCiti reports June credit loss 2.49% vs. 2.86% last month
Subscribe for More Information
13:56 EDTCEarnings Watch: Analysts mixed on Citi after settlements, asset sales
Subscribe for More Information
13:50 EDTCEarnings Watch: Goldman Sachs to report after last quarter's earnings beat
Subscribe for More Information
08:32 EDTBMYBristol-Myers Squibb, MUSC announce translational research collaboration
The Medical University of South Carolina, or MUSC, and Bristol-Myers Squibb (BMY) announced that they have entered into a translational research collaboration focused on fibrotic diseases, including scleroderma, renal fibrosis and idiopathic pulmonary fibrosis. The agreement includes studies designed to improve the mechanistic understanding of fibrosis, explore patient segmentation based on disease characteristics and/or biomarker approaches and predictors of disease progression.
07:58 EDTGILD, BIIBAnalysts break down impact of $7.2B Receptos buyout
After Celgene (CELG) announced last night that the company has agreed to acquire Receptos (RCPT) for $232 per share in cash, or a total of about $7.2B net of cash acquired, research firms have chimed in with their opinions on how the proposed deal may impact others in the biotech space. Receptos key asset is Ozanimod, which is being studied in Phase III trials for relapsing multiple sclerosis and ulcerative colitis. DERIVATIVE CALLS: Piper Jaffray analyst Edward Tenthoff told investors that he views Celgene's deal for Receptos as good for Arena Pharmaceuticals (ARNA). The analyst notes that Arena's APD334 is already showing dose-dependent decreases in circulating lymphocyte counts and that the company will initiate Phase II studies in ulcerative colitis and Crohn's disease this year. Tenthoff reiterates an Overweight rating and $7.50 price target on Arena, which has a market capitalization around $1B and closed yesterday up 8c to $4.47. In its own note to investors this morning, Nomura said Celgene's deal could put downward pressure on Biogen's (BIIB) long-term multiple sclerosis estimates. Nomura's M. Ian Somaiya contended that one-year Phase II efficacy data for Ozanimod looked as good as Novartis’s (NVS) Gilenya and Biogen's Tecfidera’s Phase III at year 2. Somaiya also wondered if rival Gilead (GILD) could be "looking for something bigger" than Receptos for its own deal, telling investors that the firm views Incyte (INCY) as Gilead's most likely takeout target. Incyte's shares closed up $4.46 at $117.46 yesterday, giving the company a market cap of about $20B. RIVAL BID?: Wedbush analyst Liana Moussatos believes another bidder may seek to acquire Receptos, noting that she previously estimated Receptos could be valued at $348 per share, or about $10.9B, in a buyout. Moussatos noted that Celgene said it expects annual peak sales for Ozanimod to reach about $4B-$6B for RMS and UC, making its acquisition price of $7.2BN only a bit more than about 1X peak sales without accounting for other possible indications or the rest of its pipeline. Moussatos told investors she sees "plenty" of potential upside to justify a rival bidder stepping in and reiterated the firm's Outperform rating on Receptos shares. PRICE ACTION: In pre-market trading, Receptos rose 10% to $228.61 while Gilead gained 1.4% to about $119 per share.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use